STOCK TITAN

Amarin Corp Plc - AMRN STOCK NEWS

Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.

Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.

Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.

In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:

  • Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
  • Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
  • Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
  • Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.

Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.

For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.

Rhea-AI Summary

Amarin Corporation plc (AMRN) has issued a statement correcting misinformation released by Sarissa Capital Management. Contrary to Sarissa's claims, Amarin confirmed that its registrar is accepting all proxy cards for the upcoming General Meeting of Shareholders, adhering to standard practices in contested solicitations. The registrar notified Sarissa eight hours before their release that all proxy submissions, including Sarissa's blue card, would be accepted. This clarification emphasizes Amarin's commitment to all shareholders and contradicts Sarissa's narrative, which appears to prioritize its own interests over those of Amarin's broader shareholder base.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary

Sarissa Capital has raised concerns about Amarin's handling of proxy votes, claiming that Amarin's registrar was not instructed to accept blue proxy cards as required by law. This situation is viewed as an attempt to disenfranchise shareholders. Sarissa, the largest shareholder with over 25 million shares, has ensured that all votes submitted on the blue proxy card will be counted. They urge shareholders to vote 'FOR' their nominees and the removal of Chairman Per Wold-Olsen by the February 21, 2023 deadline. Sarissa believes that Amarin requires significant change to unlock its potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.58%
Tags
none
-
Rhea-AI Summary

Sarissa Capital Management expressed concerns regarding Amarin Corporation's recent shareholder engagement webcast, deeming it tone-deaf and lacking accountability for poor performance. CEO Karim Mikhail asserted that the company met its objectives despite shareholders losing over $840M in 2022. Sarissa highlighted discrepancies, such as Mikhail's $5.8M compensation amid a 31% stock decline and Chairman Per Wold-Olsen's $1M compensation during a 64% value loss. Call for shareholder support to elect Sarissa nominees was emphasized, with the proxy vote deadline on February 21, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
Rhea-AI Summary

Amarin Corporation plc (NASDAQ: AMRN) announced a live webcast on February 14, 2023, from 8:00 a.m. to 9:00 a.m. ET. Members of the Board and management team will address shareholder questions regarding the company’s strategy and operational improvements. Shareholders can submit questions in advance. The upcoming General Meeting of Shareholders is set for February 28, 2023, with record shareholders entitled to vote. Amarin urges shareholders to vote 'AGAINST' all proposals on the WHITE proxy card. Voting deadlines vary for ADS and ordinary shares. For investor assistance, proxy solicitors are available. More information can be found at www.voteamarin.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
conferences
-
Rhea-AI Summary

Sarissa Capital Management LP has issued a statement regarding Amarin Corporation (NASDAQ: AMRN), accusing the company of wasting shareholder capital. Amarin plans to spend over $7 million to block Sarissa from board representation, which is significantly more than Sarissa's planned expenditure. The statement highlights past financial mismanagement, including substantial compensation granted to executives despite significant stock declines, totaling over $1.4 billion in shareholder losses in 2021 and 2022. Sarissa advocates for shareholder action to remove Chairman Per Wold-Olsen and supports change in leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary

Sarissa Capital Management has issued a letter urging Amarin shareholders to vote for significant changes at the company, including the appointment of new board members and the removal of Chairman Per Wold-Olsen.

They criticize Amarin’s leadership for poor performance, highlighted by a 64% decline in stock price in 2022, equating to a loss of over $840 million in shareholder value. Furthermore, Sarissa points to management’s ineffective market strategies and lack of shareholder engagement as contributing factors to Amarin's failure to capitalize on its valuable asset, Vascepa/Vazkepa.

Sarissa urges action before the February 21, 2023 voting deadline to prevent further value destruction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
Rhea-AI Summary

Amarin Corporation (NASDAQ: AMRN) has mailed a letter urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card at the scheduled General Meeting on February 28, 2023. The letter highlights a significant shift in the company's management and strategy, emphasizing that Amarin is undergoing a transformation and has the right team to drive shareholder value. The letter accuses Sarissa of misleading shareholders with a track record of value destruction, citing that companies with Sarissa-affiliated directors have seen a NEGATIVE 24% total shareholder return. Amarin's management is committed to maximizing value, including potential M&A opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary

Sarissa Capital Management urges Amarin shareholders to vote the BLUE proxy card ahead of the general meeting on February 28, 2023. Shareholders should ensure their votes are submitted by February 21, 2023. Sarissa's presentation highlights inaccuracies in Amarin's statements aimed at protecting its board, advocating for the election of Sarissa’s nominees and the removal of Chairman Per Wold-Olsen. Shareholders are encouraged to refrain from using Amarin’s WHITE proxy card, with additional details available on Sarissa's website and through its proxy solicitor, D.F. King & Co., Inc.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.22%
Tags
none
-
Rhea-AI Summary

Amarin Corporation (NASDAQ: AMRN) sent a letter to shareholders urging them to vote "AGAINST" Sarissa Capital's proposals during the upcoming General Meeting set for February 28, 2023. The company criticized Sarissa for spreading misleading information and attempting to take control of the board with underqualified nominees. Key points include Sarissa's historical negative impact on shareholder value, with a median total shareholder return of -24% at companies with Sarissa-nominated directors. Amarin emphasizes its commitment to maximizing shareholder value and has initiated cost-saving measures, achieving $50 million in reductions in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary

Sarissa Capital Management has launched a dedicated website for Amarin Corporation shareholders, emphasizing the importance of voting with the BLUE proxy card by February 21, 2023, at 11:59 PM EST. The proxy card will allow shareholders to support Sarissa's slate of nominees at Amarin's upcoming general meeting on February 28, 2023. Sarissa advises against using Amarin’s WHITE proxy card. Shareholders can access important documents via the SEC website or Sarissa's site for further instructions on voting and to view their presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none

FAQ

What is the current stock price of Amarin Plc (AMRN)?

The current stock price of Amarin Plc (AMRN) is $0.46 as of December 20, 2024.

What is the market cap of Amarin Plc (AMRN)?

The market cap of Amarin Plc (AMRN) is approximately 191.6M.

What does Amarin Corporation do?

Amarin Corporation is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, primarily through its product VASCEPA® (icosapent ethyl).

What is VASCEPA®?

VASCEPA® (icosapent ethyl) is Amarin's FDA-approved product designed to reduce cardiovascular events in high-risk patients by lowering triglyceride levels.

How did Amarin perform financially in recent quarters?

In Q1 2024, Amarin reported total net revenue of $56.5 million, with significant growth in Europe and a stable cash position of $308.2 million.

What recent strategic initiatives has Amarin undertaken?

Amarin has restructured its leadership, reported strong sales growth in Europe, implemented financial discipline measures, and announced a share repurchase plan.

What are the key markets for Amarin's products?

Amarin's key markets include the United States, Europe, Canada, China, and other regions, with ongoing efforts to expand market access and commercialization globally.

What recent achievements have boosted Amarin's market position?

Recent achievements include extending VAZKEPA's patent protection in Europe until 2039 and securing approximately 65% growth in in-market sales in Europe for Q1 2024.

How does VASCEPA® benefit patients?

VASCEPA® has been shown to significantly reduce cardiovascular events in high-risk patients with elevated triglyceride levels, offering a new treatment option beyond traditional therapies.

Who are the key executives at Amarin?

Key executives include President & CEO Patrick Holt, who brings global leadership and turnaround experience to drive the company's strategic initiatives.

What is the purpose of Amarin's share repurchase plan?

The $50 million share repurchase plan aims to enhance shareholder value by buying back shares, subject to necessary approvals.

How does Amarin support its global operations?

Amarin supports its global operations through offices in the United States, Ireland, Switzerland, and partnerships with commercial entities in various regions.

Amarin Corp Plc

Nasdaq:AMRN

AMRN Rankings

AMRN Stock Data

191.60M
404.75M
1.6%
17.05%
4.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
DUBLIN 2